RxDoctor Payments Data

Aimee Eichen, MD

Ophthalmology · Manhasset, NYNPI 1699851428

Payments from drug & device makers

$1,776in general payments, 2019–2025

Across 15 payments — averaging $118.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$502
  • Bausch & Lomb Americas Inc.$275
  • Glaukos Corporation$232
  • Genentech USA, Inc.$125
  • Omeros Corporation$125
  • Sun Pharmaceutical Industries Inc.$122
  • plus $395 from 4 others

What the payments were for

  • Food & beverage$1,776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,776 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$404,009
Medicare patients
1,311
Services billed
2,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$35,554
XiidraLifitegrast17$24,946
LumiganBimatoprost33$16,949
Timolol Maleate73$9,291
InveltysLoteprednol Etabonate25$7,168
Brimonidine Tartrate18$5,613
ProlensaBromfenac Sodium14$4,792
Alphagan PBrimonidine Tartrate19$4,385
Bromfenac Sodium27$4,164
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$3,421
Loteprednol Etabonate23$3,372
Prednisolone Acetate117$3,294
Tobramycin-DexamethasoneTobramycin/Dexamethasone63$3,071
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat125$2,878
Latanoprost181$1,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$95$56,88881 claims
Bausch & Lomb Americas Inc.Xiidra$275$24,94617 claims
Kala Pharmaceuticals, Inc.Inveltys$119$7,16825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →